PIK3CA in cancer: The past 30 years

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Phosphoinositide 3-kinase (PI3K) was initially identified as a lipid kinase linked to oncoproteins.
• Decades of research have elucidated PI3K's structure, function, and involvement in cellular signaling.
• PI3K's role as a retroviral oncogene and its direct link to cancer through mutations have been established.

Purpose of the Study:

• To review the historical progression of PI3K research over four decades.
• To highlight the increasing understanding of PI3K's involvement in cancer development and progression.
• To discuss the emergence of PI3K as a therapeutic target in oncology.

Main Methods:

• Literature review and historical analysis of PI3K research.
• Summarization of key discoveries in PI3K identification, function, and cancer association.
• Overview of the development of PI3K inhibitor therapies and clinical trials.

Main Results:

• The first decade focused on PI3Kα identification and characterization.
• Subsequent decades revealed PI3K's activators, effectors, oncogenic potential, and cancer-specific mutations.
• The third decade marked the rise of PI3K as a cancer target, leading to clinical trials.

Conclusions:

• PI3K research has advanced significantly, establishing its critical role in cancer.
• PI3K inhibitors represent a growing class of cancer therapeutics.
• Future research is expected to further elucidate PI3K functions and drive the development of novel PI3K-based cancer drugs.